Polydioxanone Drug-Release Biomaterial for Nerve Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nerve damage, particularly peripheral nerve injuries with large nerve defects or long distances, often results in inadequate axonal regeneration due to a lack of chemical and physiological cues, leading to chronic pain and loss of muscle control, as current surgical techniques fail to effectively restore sensory and functional outcomes.
Innovation Solution
A biomaterial incorporating a polymer, such as polydioxanone, combined with neuro-regenerative agents like FK506, is used to form a local drug delivery system for nerve repair, promoting axonal regeneration and tissue repair by sustained release of the agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical techniques are used to repair nerve injuries, then nerve connection is restored, but axonal regeneration is insufficient due to lack of chemical and physiological cues
Solution Approach 1:
The biomaterial is prepared in advance with incorporated neuroregenerative agents (FK506, bFGF, NGF) and immunosuppressive agents (FK506, cyclosporine A, tacrolimus) that will be released during the regeneration process. This preliminary incorporation ensures that chemical and physiological cues are available before axonal regeneration begins, addressing the lack of cues in conventional surgical repair.
Solution Approach 2:
The patent changes the chemical environment parameters at the nerve injury site by incorporating specific concentrations of neuroregenerative agents (e.g., FK506 at 0.1-10 µg/mL, bFGF at 1-100 ng/mL) and immunosuppressive agents into the biomaterial matrix. These parameter changes create optimal conditions for axonal regeneration and immune modulation that are not achieved by surgical techniques alone.
2Quantity of substance
If neuroregenerative agents are delivered systemically, then they can reach target tissues, but the concentration at the injury site is insufficient for effective regeneration
Solution Approach 1:
The biomaterial provides localized delivery of neuroregenerative agents directly at the nerve injury site, creating a high-concentration gradient where it is most needed. The agents are incorporated into the biomaterial matrix at specific local concentrations (e.g., FK506 at 0.1-10 µg/mL in the biomaterial) that are much higher than what can be achieved through systemic delivery, while maintaining precise control over the release profile.
3Speed
If the biomaterial releases drugs rapidly, then therapeutic effect is achieved quickly, but the duration of action is too short for complete nerve regeneration
Solution Approach 1:
The biomaterial is designed to release neuroregenerative and immunosuppressive agents in a periodic or sustained manner over an extended period (weeks to months). The controlled release mechanism maintains therapeutic concentrations of agents like FK506 and bFGF throughout the regeneration process, providing both initial rapid effect and prolonged sustained action necessary for complete nerve regeneration.
Data Source
AI summary
A method of preparing an implantable biomaterial includes combining a polymer comprising polydioxanone with a neuro-regenerative agent or an immunosuppressive agent comprising at least one immunophilin ligand, and melting the polymer. The method further includes extruding the combined polymer and the neuro-regenerative agent or immunosuppressive agent to form the implantable biomaterial.